Allogene Net Invested Capital from 2010 to 2025
| ALLO Stock | USD 1.62 0.01 0.61% |
Net Invested Capital | First Reported 2020-03-31 | Previous Quarter 463.7 M | Current Value 422.2 M | Quarterly Volatility 247.3 M |
Check Allogene Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Allogene Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 171.9 K, Selling General Administrative of 62.4 M or Total Revenue of 20.9 K, as well as many indicators such as Price To Sales Ratio of 19.8 K, Dividend Yield of 0.0 or PTB Ratio of 1.03. Allogene financial statements analysis is a perfect complement when working with Allogene Therapeutics Valuation or Volatility modules.
Allogene | Net Invested Capital |
Latest Allogene Therapeutics' Net Invested Capital Growth Pattern
Below is the plot of the Net Invested Capital of Allogene Therapeutics over the last few years. It is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. Allogene Therapeutics' Net Invested Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Allogene Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Invested Capital | 10 Years Trend |
|
Net Invested Capital |
| Timeline |
Allogene Net Invested Capital Regression Statistics
| Arithmetic Mean | 350,383,961 | |
| Geometric Mean | 1,161,230 | |
| Coefficient Of Variation | 111.13 | |
| Mean Deviation | 350,385,961 | |
| Median | 422,179,000 | |
| Standard Deviation | 389,393,831 | |
| Sample Variance | 151627.6T | |
| Range | 1.1B | |
| R-Value | 0.75 | |
| Mean Square Error | 71199.8T | |
| R-Squared | 0.56 | |
| Significance | 0.0008 | |
| Slope | 61,300,027 | |
| Total Sum of Squares | 2274413.3T |
Allogene Net Invested Capital History
About Allogene Therapeutics Financial Statements
Allogene Therapeutics investors utilize fundamental indicators, such as Net Invested Capital, to predict how Allogene Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Invested Capital | 422.2 M | 677.7 M |
Check out the analysis of Allogene Therapeutics Correlation against competitors. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.